Active, not recruitingPhase 1NCT05382325
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
Studying Autosomal dominant multiple pterygium syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- MK-1484(biological)
- Enrollment
- 70 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (8)
- Sanford Cancer Center ( Site 0005), Sioux Falls, South Dakota, United States
- NEXT Oncology ( Site 0001), San Antonio, Texas, United States
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011), Toronto, Ontario, Canada
- Rambam Health Care Campus-Oncology ( Site 0021), Haifa, Israel
- Sheba Medical Center-ONCOLOGY ( Site 0020), Ramat Gan, Israel
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035), Amsterdam, North Holland, Netherlands
- Erasmus Medisch Centrum-Medical Oncology ( Site 0036), Rotterdam, South Holland, Netherlands
- Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037), Utrecht, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05382325 on ClinicalTrials.govOther trials for Autosomal dominant multiple pterygium syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06941012Validation of α-synuclein Modifications in Parkinson's dIsoRder EvolutionCasa di Cura IGEA
- RECRUITINGNCT06949670Alpha-Synuclein PET/CT in Various α-Syn-Related DiseaseTianjin Medical University
- RECRUITINGPHASE3NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05281003Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)Fudan University
- RECRUITINGNCT07533799The Swedish BioFINDER Sleep StudySkane University Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCAstraZeneca
- RECRUITINGPHASE1, PHASE2NCT04938817Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Merck Sharp & Dohme LLC
- RECRUITINGNCT04724941Prodromal Alpha-Synuclein Screening in Parkinson's Disease StudyUniversity Hospital Schleswig-Holstein
See all trials for Autosomal dominant multiple pterygium syndrome →